GlaxoSmithKline/Vir launches phase 2/3 clinical trial of new coronary and antibody.

Recently, Vir Biotechnology and GlaxoSmithKline (GSK) announced that the new coronavirus and antibody VIR-7831 (also known as GSK4182136) jointly developed by the two companies have completed the first patient in phase 2/3 clinical trials.
phase 2/3 clinical trial, called COMET-ICE, is expected to register nearly 1,300 patients with early symptomatic COVID-19, with the aim of assessing whether a single dose of VIR-7831 injections can prevent coVID-19 hospitalization.
expected preliminary results to be available by the end of this year and to be fully resulted in the first quarter of 2021.
feature of the new coronavirus is the prickly protein that covers the outer surface of the virus.
the virus uses these prickly proteins to combine with a subject on the surface of human cells and enter the cells, leading to infection.
VIR-7831 median antibody found through Vir's antibody platform has been shown in preclinical studies to be affinity with the new coronavirus pyrethroid protein and to exhibit strong new coronavirus melioth.
addition, the VIR-7831 is designed to improve its biousability in the lungs.
Later this year, the two companies are expected to launch another Phase 2 trial of the antibody VIR-7832, which has the same properties as VIR-7831 but may also serve as a treatment and/or preventive vaccine.
()